Rawcliffe Adrian — SEC insider filings
SEC reporting owner CIK 1555851. 35 insider filings on record with FilingPulse; latest filed 2026-10-07.
Transaction summary — filings shown
Covers all 35 filings on record, filed 2020-08-20 to 2026-10-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 29 legs across 23 filings — 346,281 shares, $1,275,807 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 42,000 shares @ $15.00 ($630,000) in Wave Life Sciences, Inc., filed 2025-12-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | Director | 10 | — | 3 legs · 70,815 sh · $806,604 | 12 |
| Adaptimmune Therapeutics PLC (ADAP) | Chief Executive Officer, Director | 25 | — | 26 legs · 275,466 sh · $469,203 | 10 |
Insider filings — Rawcliffe Adrian
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-07 | 4 | Wave Life Sciences, Inc. (WVE) | Grant/award (A): 10,700 @ $0 · Grant/award (A): 64,000 (derivative) @ $0 | EDGAR |
| 2026-08-13 | 4 | Wave Life Sciences, Inc. (WVE) | Sale (S): 12,700 @ $5.29 | EDGAR |
| 2025-12-10 | 4 | Wave Life Sciences Ltd. (WVE) | Option exercise (M): 42,000 @ $5.97 · Sale (S): 42,000 @ $15 · Option exercise (M): 42,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Wave Life Sciences Ltd. (WVE) | Sale (S): 16,115 @ $6.79 | EDGAR |
| 2025-08-13 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 12,700 @ $0 · Grant/award (A): 76,200 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 5,143,248 (derivative) @ $0 · Grant/award (A): 3,428,832 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 30,601 @ $0.58 | EDGAR |
| 2025-01-15 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 12,539 @ $0.59 · Sale (S): 17,934 @ $0.59 · Sale (S): 29,096 @ $0.57 | EDGAR |
| 2024-08-14 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 16,115 @ $0 · Grant/award (A): 32,230 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 7,633,296 (derivative) @ $0 · Grant/award (A): 1,696,272 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 9,304 @ $0.79 · Sale (S): 30,080 @ $0.67 | EDGAR |
| 2024-01-12 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 11,945 @ $0.84 · Sale (S): 17,257 @ $0.85 | EDGAR |
| 2023-09-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,403 @ $0.78 | EDGAR |
| 2023-08-09 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-06-27 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,333 @ $0.92 | EDGAR |
| 2023-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 4,690,224 (derivative) @ $0 · Grant/award (A): 1,798,272 (derivative) @ $0 | EDGAR |
| 2023-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 10,057 @ $1.86 | EDGAR |
| 2023-01-12 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 13,042 @ $1.75 · Sale (S): 18,763 @ $1.71 | EDGAR |
| 2023-01-04 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 5,073 @ $1.69 | EDGAR |
| 2022-09-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,536 @ $1.97 | EDGAR |
| 2022-08-17 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,562 @ $1.63 | EDGAR |
| 2022-01-18 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 11,096 @ $3.19 | EDGAR |
| 2022-01-13 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 4,690,224 (derivative) @ $0 · Grant/award (A): 1,047,480 (derivative) @ $0 | EDGAR |
| 2022-01-13 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 14,362 @ $3.56 · Sale (S): 3,046 @ $3.54 | EDGAR |
| 2022-01-05 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 5,532 @ $4.06 | EDGAR |
| 2021-09-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,782 @ $5.20 | EDGAR |
| 2021-08-18 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,794 @ $4.37 | EDGAR |
| 2021-01-19 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 9,879 @ $5.67 | EDGAR |
| 2021-01-12 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,707 @ $6.15 | EDGAR |
| 2021-01-11 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 3,260,400 (derivative) @ $0 · Grant/award (A): 728,160 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 4,967 @ $5.33 | EDGAR |
| 2020-09-02 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 2,776 @ $8.51 | EDGAR |
| 2020-08-20 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1555851 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs